𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

✍ Scribed by Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Hong; Coleman Obasaju; Eduardo J. Pennella; Allicia C. Girvan; Susan C. Guba


Book ID
119935615
Publisher
CIG Media Group, LP.
Year
2009
Tongue
English
Weight
100 KB
Volume
10
Category
Article
ISSN
1525-7304

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES